Cormorant Asset Management as of Sept. 30, 2019
Portfolio Holdings for Cormorant Asset Management
Cormorant Asset Management holds 71 positions in its portfolio as reported in the September 2019 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
Mirati Therapeutics | 11.1 | $183M | 2.4M | 77.91 | |
Turning Point Therapeutics I | 8.1 | $133M | 3.5M | 37.60 | |
Spdr S&p 500 Etf (SPY) | 7.2 | $119M | 400k | 296.77 | |
Biohaven Pharmaceutical Holding | 4.8 | $79M | 1.9M | 41.72 | |
Apellis Pharmaceuticals (APLS) | 4.4 | $72M | 3.0M | 24.09 | |
Ascendis Pharma A S (ASND) | 4.2 | $69M | 718k | 96.32 | |
Reata Pharmaceuticals Inc Cl A | 4.0 | $66M | 820k | 80.29 | |
Bridgebio Pharma (BBIO) | 3.4 | $56M | 2.6M | 21.47 | |
Crispr Therapeutics (CRSP) | 2.7 | $44M | 1.1M | 40.99 | |
Stoke Therapeutics (STOK) | 2.3 | $38M | 1.8M | 21.49 | |
Principia Biopharma | 2.3 | $38M | 1.3M | 28.24 | |
Blueprint Medicines (BPMC) | 2.2 | $36M | 493k | 73.47 | |
Uniqure Nv (QURE) | 2.2 | $35M | 900k | 39.36 | |
Allakos (ALLK) | 2.1 | $35M | 444k | 78.63 | |
Tricida | 2.0 | $33M | 1.1M | 30.87 | |
Axonics Modulation Technolog (AXNX) | 2.0 | $33M | 1.2M | 26.92 | |
SPDR S&P Biotech (XBI) | 1.9 | $31M | 400k | 76.25 | |
Quotient | 1.7 | $28M | 3.6M | 7.77 | |
Nextcure (NXTC) | 1.7 | $27M | 885k | 30.85 | |
Deciphera Pharmaceuticals | 1.6 | $27M | 789k | 33.94 | |
Rocket Pharmaceuticals (RCKT) | 1.5 | $25M | 2.1M | 11.65 | |
Myokardia | 1.4 | $23M | 443k | 52.15 | |
Y Mabs Therapeutics (YMAB) | 1.4 | $23M | 884k | 26.06 | |
Galapagos Nv- (GLPG) | 1.4 | $23M | 150k | 152.36 | |
Anaptysbio Inc Common (ANAB) | 1.3 | $21M | 591k | 34.99 | |
Amarin Corporation (AMRN) | 1.2 | $20M | 1.3M | 15.16 | |
Eidos Therapeutics | 1.2 | $19M | 541k | 35.97 | |
Kura Oncology (KURA) | 1.1 | $19M | 1.2M | 15.17 | |
Akero Therapeutics (AKRO) | 1.0 | $17M | 741k | 22.75 | |
Sarepta Therapeutics (SRPT) | 1.0 | $17M | 222k | 75.32 | |
Twist Bioscience Corp (TWST) | 1.0 | $16M | 687k | 23.88 | |
Argenx Se (ARGX) | 0.9 | $15M | 128k | 113.96 | |
Nektar Therapeutics (NKTR) | 0.9 | $14M | 789k | 18.22 | |
Satsuma Pharmaceuticals Ord | 0.8 | $13M | 858k | 15.01 | |
Sage Therapeutics (SAGE) | 0.8 | $12M | 89k | 140.29 | |
Chemocentryx | 0.8 | $12M | 1.8M | 6.78 | |
Health Sciences Acqustn Corp unit 04/01/2024 | 0.7 | $12M | 1.1M | 10.73 | |
X4 Pharmaceuticals (XFOR) | 0.7 | $11M | 882k | 12.71 | |
Inspire Med Sys (INSP) | 0.6 | $11M | 172k | 61.02 | |
Gossamer Bio (GOSS) | 0.6 | $10M | 618k | 16.79 | |
Eiger Biopharmaceuticals | 0.6 | $10M | 998k | 10.25 | |
Zai Lab (ZLAB) | 0.6 | $9.0M | 277k | 32.35 | |
Harpoon Therapeutics | 0.5 | $8.9M | 650k | 13.66 | |
Avrobio Ord (AVRO) | 0.5 | $8.0M | 568k | 14.12 | |
Orchard Therapeutics Plc ads | 0.5 | $8.0M | 675k | 11.88 | |
Arena Pharmaceuticals | 0.5 | $7.9M | 172k | 45.77 | |
Constellation Pharmceticls I | 0.5 | $7.8M | 1.2M | 6.46 | |
Ra Pharmaceuticals | 0.4 | $7.0M | 296k | 23.65 | |
Autolus Therapeutics Plc spon ads (AUTL) | 0.4 | $6.0M | 480k | 12.42 | |
Genfit S A ads (GNFT) | 0.3 | $5.2M | 300k | 17.41 | |
Atreca Inc Cl A (BCEL) | 0.3 | $5.0M | 406k | 12.24 | |
Minerva Neurosciences | 0.3 | $4.7M | 608k | 7.75 | |
Homology Medicines | 0.3 | $4.4M | 245k | 18.10 | |
Atara Biotherapeutics | 0.3 | $4.2M | 300k | 14.12 | |
Precision Biosciences Ord | 0.2 | $3.9M | 468k | 8.39 | |
Rubius Therapeutics | 0.2 | $3.9M | 492k | 7.85 | |
Neurocrine Biosciences (NBIX) | 0.2 | $3.5M | 39k | 90.10 | |
Phasebio Pharmaceuticals | 0.2 | $3.4M | 816k | 4.17 | |
Kezar Life Sciences (KZR) | 0.2 | $3.0M | 928k | 3.28 | |
Igm Biosciences (IGMS) | 0.2 | $2.8M | 156k | 17.75 | |
Iterum Therapeutics | 0.1 | $2.3M | 396k | 5.90 | |
Adverum Biotechnologies | 0.1 | $1.6M | 300k | 5.45 | |
Audentes Therapeutics | 0.1 | $1.4M | 50k | 28.10 | |
Acceleron Pharma | 0.1 | $988k | 25k | 39.52 | |
G1 Therapeutics | 0.1 | $1.0M | 1.0k | 1025.00 | |
Scholar Rock Hldg Corp (SRRK) | 0.1 | $1.1M | 119k | 8.95 | |
Inflarx Nv (IFRX) | 0.1 | $741k | 300k | 2.47 | |
Abeona Therapeutics | 0.0 | $452k | 200k | 2.26 | |
Aclaris Therapeutics (ACRS) | 0.0 | $270k | 250k | 1.08 | |
Outlook Therapeutics Inc *w exp 02/18/201 | 0.0 | $50k | 417k | 0.12 | |
Outlook Therapeutics | 0.0 | $23k | 16k | 1.46 |